Talcum Powder Lawsuits: Johnson and Johnson's $9 Billion Settlement Explained

A $9 Billion Settlement and a Controversial Bankruptcy Strategy

Johnson & Johnson's talcum powder litigation is one of the most consequential mass tort battles in American legal history. More than 60,000 plaintiffs alleged that J&J's baby powder caused ovarian cancer or mesothelioma, and the company responded with a controversial legal maneuver: creating a subsidiary called LTL Management, loading it with the talc liabilities, and filing it for bankruptcy — a strategy critics called the "Texas Two-Step." After two failed bankruptcy attempts, J&J proposed a $9 billion settlement in 2024 through a third bankruptcy filing, covering claims from tens of thousands of women with ovarian cancer. Whether that settlement ultimately takes effect remains the subject of ongoing litigation.

The talc litigation forced the pharmaceutical and consumer products industry to confront both the science of chemical carcinogenesis and the legal architecture of mass tort resolution.

The Science: Talc, Asbestos, and Cancer Risk

Talc is a naturally occurring mineral often mined alongside asbestos. The central allegations in talc litigation are two distinct but related claims:

• Asbestos contamination: That some talcum powder products contained trace asbestos fibers, a known carcinogen, capable of causing mesothelioma — a rare and aggressive cancer of the lung lining or abdomen.
• Talc itself as carcinogen: That perineal (genital) use of talcum powder, applied to underwear or directly to the genitals, increases ovarian cancer risk independently of any asbestos content, potentially through inflammatory mechanisms as talc particles migrate to the ovaries.

The International Agency for Research on Cancer (IARC) classified perineal use of talc as "possibly carcinogenic to humans" (Group 2B) in 2006 and elevated that classification to "probably carcinogenic" (Group 2A) in 2024. Epidemiological studies show a modest elevated risk — relative risks of 1.2 to 1.5 in most meta-analyses — though the absolute risk increase is small given the baseline rarity of ovarian cancer.

The Internal Document Problem

J&J's litigation exposure expanded dramatically when internal company documents were disclosed through discovery. Reuters published an investigation in 2018 revealing that J&J scientists and executives had known since at least the 1970s that raw talc and some finished baby powder products tested positive for small amounts of asbestos. The documents showed ongoing concerns about asbestos contamination that were not disclosed to regulators or consumers. These revelations fueled a wave of additional lawsuits and drove jury verdicts, including a 2018 Missouri verdict of $4.69 billion (later reduced on appeal) for 22 women with ovarian cancer.

Landmark Verdicts and Appellate Reversals

The appellate reductions illustrate a recurring pattern: plaintiff-friendly jury awards are often reduced significantly on post-trial review for procedural or damages-calculation reasons, even when liability findings are upheld.

The Texas Two-Step Bankruptcy Strategy

To halt the litigation, J&J used a divisional merger permitted under Texas law to create LTL Management LLC, transferring talc liabilities to this new entity while leaving J&J's operating businesses unaffected. LTL then filed for Chapter 11 bankruptcy, triggering an automatic stay that halted all pending litigation. The strategy proved deeply controversial — bankruptcy courts are designed for genuinely insolvent debtors, and critics argued J&J was using bankruptcy as a litigation-avoidance tool while remaining financially robust.

The Third Circuit Court of Appeals dismissed LTL's first bankruptcy in January 2023, ruling the subsidiary was not in financial distress at filing. A second attempt failed in 2024. J&J's third attempt, paired with a proposed $9 billion settlement fund, seeks approval from claimants and the bankruptcy court.

What the Settlement Offers Claimants

• Eligible conditions: Ovarian cancer, fallopian tube cancer, peritoneal cancer, and mesothelioma linked to talc product use.
• Compensation structure: A trust fund would distribute payments based on diagnosis, disease severity, and duration of product use.
• Trade-off: Acceptance requires releasing all claims against J&J and its affiliates permanently, foreclosing future litigation even for claimants whose conditions worsen.
• Opt-out rights: Claimants who reject the settlement must navigate how to proceed given the bankruptcy stay.

Regulatory Response

In 2020, J&J voluntarily discontinued its talc-based baby powder in the U.S. and Canada, citing declining sales driven by "misinformation" and "unfounded media reports." In 2023, the company announced it would discontinue talc-based products globally by 2024, replacing them with cornstarch-based formulations. The FDA had strengthened testing requirements for talc in cosmetics following asbestos contamination findings in several products from multiple manufacturers.

This article is for informational purposes only and does not constitute legal advice.